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TO THE EDITOR
The active form of vitamin D, 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3),
has a number of desirable properties in
addition to its classical effect on bone
and calcium metabolism. These include
immunomodulatory, anti-inflammatory,
and anti-fibrotic properties; however,
its use is limited because of the toxic
(calcemic) effect at therapeutically rele-
vant doses (Szodoray et al., 2008; Bikle,
2010). Our goal in this and related
studies has been to identify natural
noncalcemic vitamin D analogs for use
as therapeutic agents to treat diseases
like scleroderma and/or autoimmune
diseases.
We embarked upon a strategy to
produce such agents with a short or long
side chain. Specifically, we defined a, to
our knowledge previously unreported,
steroidogenic pathway initiated by clea-
vage of the side chain of 7-dehydro-
cholestrol by P450scc to produce
7-dehydropregnenolone (7DHP), which
could be further converted to hydroxy-
5,7-dienal intermediates by classical
steroidogenic enzymes (Slominski et al.,
2004, 2009). An example of the
latter is 17,20-dihydroxy7DHP (17,20
(OH)27DHP) (Shackleton et al., 2002),
for which we established a chemical
route of synthesis (5Z with UVB-induced
transformation to vitamin D-like 17,20-
dihydroxypregnacalciferol,7E-3b,17,20-tri-
hydroxy-9,10-secopregna-5,7,10 triene)
(17,20(OH)2pD) and lumisterol-like struc-
tures (Zmijewski et al., 2009).
As 17,20(OH)27DHP is produced in
the body, at least under pathological
conditions (Smith LemliOptiz syn-
drome) (Shackleton et al., 2002), and
it can be transformed in the skin to
corresponding secosteroids when ex-
posed to UVB (Slominski et al., 2004;
Zmijewski et al., 2009), these vitamin
D-like hydroxyproducts are good can-
didates to serve as natural products,
which by definition would have low
toxicity. Supporting this, shortening of
the side chain of vitamin D eliminates
its calcemic activity (Holick et al.,
1975). Thus, these, to our knowledge
previously unreported, vitamin D
analogs could serve as candidates for
treatment of autoimmune or fibro-
sing diseases, as vitamin D3 displays
well-documented effects on these
conditions in animal models (Moro
et al., 2008).
17,20(OH)2pD and lumisterol deri-
vatives were synthesized as described
previously (Zmijewski et al., 2009). For
details, see Supplementary Figure S1
online.
Female C57BL/6 mice, 6 weeks
old, were purchased from Jackson
Labs (Bar Harbor, ME) and maintained
on a regular laboratory chow diet.
The experiments were approved by
the local IACUC. Mice were divided
into groups of three to receive one
of the following treatments by daily
intraperitoneal injection for 14 days:
sterile sesame oil (50 ml) (Sigma Chemi-
cal, St Louis, MO), or 3 mg kg1 17,20R
(OH)2pD or 17,20S(OH)2pD dissolved
in 50 ml sterile sesame oil. Mice
tolerated the injections well without
signs of clinical distress. On day 15
mice were euthanized, and sera were
obtained for measurement of total
Ca2þ by atomic absorption spectropho-
tometry (Bhattacharya, 1977), inorganic
phosphate by Malachite Green Assay
Kit (Cayman Chemical, Ann Arbor,
MI), and fibroblast growth factor
(FGF)23 by ELISA (Immuntopics, San
Clemente, CA). Bone mineral density
and bone mineral content were deter-
mined for whole-body (excluding the
head) and excised soft tissue-cleaned
femurs by dual-energy X-ray absorp-
tiometry, using a GE Lunar PIXImus
(GE Lunar Corporation, Madison, WI);
quality control and calibration were
carried out within 24 hours of each
scanning period. An Instron Universal
Test System (Instron model 5567, In-
stron, Norwood, MA) was used for
three-point bending (gap size, 7mm)
to determine the flexure stress of
mouse femoral diaphyses. The load was
applied at a constant displacement of
5mmmin1 to failure. The femurs broke
in the mid-diaphyseal region, and data
were recorded as flexure stress in mega-
pascals. Hearts, livers, spleens, and
kidneys were processed for histology.
Human dermal fibroblasts were
grown in 24-well Costar tissue culture
plates to assess the effect of vitamin D
analogs on total collagen protein
(Raghow et al., 1987), hyaluronan
(Postlethwaite et al., 1989), type I
collagen by ELISA (Chondrex, Red-
mond, WA), or Col1A1 mRNA by quan-
titative reverse transcriptase in real time.
We previously showed that 20-hy-
droxyvitamin D3 (20(OH)D3) at a dose
as high as 3.0 mg kg1 in rats has no
calcemic activity (calcium¼10.4±
1.5mgdl1 (mean±SD) vs. 9.3±1.3
mgdl1 for control), whereas 1,25
(OH)2D3 at the same dose had
the expected strong calcemic effect,
raising calcium concentration to 16.0±
1.2mgdl1 (Slominski et al., 2010).
In this study, we have found that
17,20S(OH)2pD and 17,20R(OH)2pD
at doses of 3 mg kg1 had no significant
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Abbreviations: 1,25(OH)2D3, 1,25-dihydroxyvitamin D3; 17,20(OH)2pD, 17,20-
dihydroxypregnacalciferol; 20(OH)D3, 20-hydroxyvitamin D3; 7DHP, 7-dehydropregnenolone;
17,20(OH)2pL, 17,20-dihydroxypregnalumisterol; 17,20(OH)27DHP, 17,20-dihydroxy7DHP; FGF,
fibroblast growth factor; TGF-b1, transforming growth factor-b1
effects on sera total Ca2þ levels
(Table 1). Examination of histological
sections of the hearts, kidneys, liver,
and spleen revealed lack of calcifi-
cations or identifiable toxicity (not
shown). Thus, 17,20R(OH)2pD and
17,20R(OH)2pD show the same non-
calcemic properties as the structurally
similar 20(OH)pD (Holick et al., 1975)
and 20(OH)D3 (Slominski et al., 2010).
Serum levels of the phosphatonin
factor, FGF23, were not different in
mice treated with sesame oil or 17,20S
(OH)2pD (Table 1). However, 17,20R
(OH)2pD did induce a significant eleva-
tion in serum levels of FGF23 (Table 1).
When rats were administered 1,25
(OH)2D3, serum levels of FGF23
increase dramatically (45-fold increase
by 0.3 mg kg1 1,25(OH)2D3) and
inorganic phosphate in sera is markedly
reduced (Saito et al., 2005). In vitro,
addition of 1,25(OH)2D3 to cultures of
osteoblasts increases FGF23 mRNA
levels (Liu et al., 2006). In this study,
levels of inorganic phosphate in sera
were not significantly different bet-
ween mice treated with sesame oil
versus17,20R(OH)2pDor17,20S(OH)2pD
(Table 1). The data suggest that 17,20R
(OH)2pD has retained a weak ability to
modestly increase FGF23 levels in serum,
but not sufficiently high to significantly
reduce serum inorganic phosphate,
whereas 17,20S(OH)2pD does not pos-
sess this FGF23-regulatory property of
1,25(OH)2D3. There were no differences
in bone mineral density, bone mineral
content, or flexure stress between 17,20S
(OH)2D3-, 17,20R(OH)2D3-, and sesame
oil-treated mice (Table 1).
Table 2 shows that R and S forms
of 17,20(OH)2pD and 17,20-dihydroxy-
pregnalumisterol (17,20(OH)2pL), like
1,25(OH)2D3, significantly inhibit TGF-
b1-induced total collagen protein
and hyaluronan production by human
dermal fibroblasts. We found no
significant differences in fibroblast
numbers per well and no significant
differences in trypan blue exclusion. In
agreement, 107 M 17,20S(OH)2pD or
17,20R(OH)2pD inhibited the TGF-b1-
stimulated expression of Col1A1 mRNA
(Supplementary Figure S2 online), and
secreted type I collagen protein (Sup-
plementary Figure S2 online, inset).
In conclusion, dihydroxy secosteroi-
dal derivatives with a short side chain
(which are to our knowledge prev-
iously unreported) are noncalcemic and
exhibit antifibrotic activity; therefore,
they are excellent candidates for further
testing in in vivo models of fibrosis and
scleroderma.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported by NIH/NIAMS Grant
R01A052190 (AS) and a Merit Review Award from
the US Department of Veteran Affairs (AEP).
Table 1. Serum calcium levels, serum FGF-23 levels, and bone measurements in mice
Group
Ca2+
(mgdl1±SEM)1
iP
(mgdl1±SEM)
FGF23
(pgml1±SEM)
BMD1 right femur
(g cm2±SEM)
BMC1 right
femur (g)
BMD1 total
(g cm2±SEM)
BMC1
total (g)
Flexure
stress1 (mPa)
Sesame oil 9.5±0.3 7.35±0.36 452±93 0.0421±0.0016 0.0100±0.0006 0.0333±0.0011 0.188±0.0110 51.3167±0.602
17,20R(OH)2pD 9.4±0.3 6.77±0.28 980±135
2 0.0464±0.0027 0.0117±0.0009 0.0352±0.0004 0.209±0.0120 49.8713±0.711
17,20S(OH)2pD 8.9±0.2 6.32±0.03 634±143 0.0450±0.0021 0.0110±0.0010 0.0342±0.0009 0.196±0.0153 48.0900±0.836
Abbreviations: BMC, bone mineral content; BMD, bone mineral density; FGF, fibroblast growth factor; iP, inorganic phosphate.
1Serum total Ca2+ and iP levels, BMD for right femur or total skeleton, BMC for right femur or total skeleton, and flexure stress in 17,20R(OH)2pD- or
17,20S(OH)2pD-treated mice were not statistically different from sesame oil control-treated mice by analysis of variance (ANOVA).
2P=0.032 by ANOVA.
Table 2. Inhibition of total collagen and hyaluronan production by novel secosteroids in human dermal fibroblasts
stimulated by TGF-b11
Condition: h TGF-b1 5ngml1;
secosteroids at 1010 M
Collagen CPM per well
(mean±SEM)105 FB (fibroblasts) P-value
Hyaluronan CPM per well
(mean±SEM)105 FB P-value
TGF-b1+vehicle 829±171 o0.001 1,556±511 o0.001
TGF-b1+17,20R(OH)2pD 330±17
2 o0.001 163±82 o0.001
TGF-b1+17,20S(OH)2pL 266±6
2 o0.001 97±462 o0.001
TGF-b1+17,20S(OH)2pD 95±10
2 o0.001 662±1892 0.01
TGF-b1+17,20R(OH)2pL 320±3
2 o0.001 222±132 o0.001
TGF-b1+1,25(OH)2,D3 310±100
2 0.007 297±182 o0.001
Abbreviations: CPM, counts per minute; TGF, transforming growth factor.
1Significantly different (Po0.001) from PBS+vehicle.
2Significantly different (Po0.001) from TGF-b1+vehicle.
After 2 hours of preincubation, h (human) TGF-b1 (R and D systems; Minneapolis, MN) was added at a final concentration of 5 ngml1. To measure total
collagen and hyaluronan production, after 48 hours of culture, plate wells were paused with 1mCI 3[H]-proline. Then, after 24 hours, culture supernatants
were harvested and collagenase-sensitive protein was determined as previously described (Raghow et al., 1987).
n=3; statistical analysis was performed using Student’s t-test.
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TO THE EDITOR
Alopecia areata (AA) is a common hair-
loss disorder that affects approximately
1–2% of the general population
(Safavi et al., 1995). The occurrence
of familial AA is well established
(Blaumeiser et al., 2006), and the
pattern of familiality strongly suggests
that its genetic basis is multifactorial.
Our current understanding of the etio-
pathogenesis of AA is incomplete, but
the condition is thought to be a tissue-
specific autoimmune disease directed
against the hair follicle (Tobin, 2003).
Numerous studies in the past
decade have reported an association
between variants of the gene coding for
the cytotoxic T lymphocyte antigen-4
(CTLA4) and some of the autoimmune
diseases, including Graves’ disease,
antineutrophil cytoplasmic antibo-
dy–associated vasculitis, type 1 dia-
betes, and rheumatoid arthritis
(Kristiansen et al., 2000; Ueda et al.,
2003). CTLA4 is a costimulatory
molecule that is expressed on activated
T cells and is involved in the negative
regulation of T-cell activation (Brunet
et al., 1987). Given the autoimmune
component shared by the various
autoimmune diseases, we aimed to
investigate the role of CTLA4 in the
development of AA. We performed a
high-resolution association analysis
of the CTLA4 gene locus using 22
tagging single-nucleotide polymorph-
isms (SNPs) in a sample of 1,196
unrelated AA patients and 1,280 con-
trols of Central European origin. During
the final preparation of this report, a
genome-wide association study was
published by Petukhova et al. (2010)
that implicates several new gene loci
for AA, including CTLA4.
In our study, eight variants showed
nominal significance in the combined
sample (Table 1). The strongest associa-
tion was found for rs3087243, which is
located 236 bp downstream of CTLA4
(Figure 1). This had a nominal P-value
(Pnom) of 4.66107 and an odds ratio
Abbreviations: AA, alopecia areata; CTLA4, cytotoxic T lymphocyte antigen-4; OR, odds ratio;
SNP, single-nucleotide polymorphism
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